Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Ledipasvir/Sofosbuvir

Hepatocellular carcinoma

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lkhagvadorj K, et al. The Risk of Hepatocellular Carcinoma in a Patient with HCV Infection after Direct-acting Antiviral Agents. Gut and Liver 11 (Suppl. 6): 171 abstr. P-LI-009, Jan 2017. Available from: URL: https://dx.doi.org/10.5009/gnl17028 [abstract] Lkhagvadorj K, et al. The Risk of Hepatocellular Carcinoma in a Patient with HCV Infection after Direct-acting Antiviral Agents. Gut and Liver 11 (Suppl. 6): 171 abstr. P-LI-009, Jan 2017. Available from: URL: https://​dx.​doi.​org/​10.​5009/​gnl17028 [abstract]
Metadaten
Titel
Ledipasvir/Sofosbuvir
Hepatocellular carcinoma
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55229-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Antineoplastics

Case report

Multiple drugs

Case report

Multiple drugs